Metrics

  • citations in SCIndeks: 0
  • citations in CrossRef:0
  • citations in Google Scholar:[]
  • visits in previous 30 days:15
  • full-text downloads in 30 days:1

Contents

article: 1 from 5  
Back back to result list
2018, vol. 37, iss. 2, pp. 45-50
Dual antiplatelet therapy in coronary artery disease
aUniversity of Belgrade, Faculty of Medicine, Institute of Histology and Embryology
bUniversity of Kragujevac, Faculty of Medical Sciences, Department of Internal Medicine
cClinical Center of Serbia, Clinic for Cardiology, Belgrade
dClinical Center of Serbia, Clinic for Cardiology, Belgrade + University of Belgrade, Faculty of Medicine

emailmilojetomasevic@gmail.com
Abstract
Coronary artery disease encompasses a spectrum of clinical presentations caused by underlying coronary atherosclerosis. Acute manifestations of atherosclerotic disease occur when rupture/erosion of atherosclerotic plaque becomes substrate for platelet activation and aggregation, which have a central role in the formation and propagation of intracoronary thrombi. Therefore, antiplatelet therapy represents a standard of care in the primary and secondary prevention of CAD. Dual antiplatelet therapy (DAPT) typically refers to aspirin along with P2Y12 receptor inhibitor (clopi-dogrel, prasugrel or ticagrelor). Choice and duration of DAPT requires an individual approach and assessment of each patient, emphasizing the tailored antiplatelet treatment. This is largely driven by patient's clinical presentation (stable coronary artery disease or acute coronary syndrome), existing risk factors (ischemic vs. hemorrhagic risk), and following treatment plan (medical treatment, percu-taneous coronary intervention, or coronary artery bypass graft). In this review, we present the evidence supporting DAPT administration and therapy duration in different subpopulations of patients with CAD. Also, we will review these data in the context of current 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease, emphasizing the novelties from the present guidelines.
References
Angiolillo, D.J. (2009) Antiplatelet Therapy in Diabetes: Efficacy and Limitations of Current Treatment Strategies and Future Directions. Diabetes Care, 32(4): 531-540
Angiolillo, D.J., Fernandez-Ortiz, A., Bernardo, E. (2007) Variability in individual responsiveness to clopidogrel: clinical implications, management, and future perspectives. J Am Coll Cardiol, 49(14): 1505-16
Baigent, C., Blackwell, L. (2009) Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet, 373(9678): 1849-1860
Bates, E.R., Lau, W.C., Bleske, B.E. (2005) Loading, Pretreatment, and Interindividual Variability Issues With Clopidogrel Dosing. Circulation, 111(20): 2557-2559
Bhatt, D.L., Fox, K., Hacke, W. (2006) Clopidogrel and Aspirin versus Aspirin Alone for the Prevention of Atherothrombotic Events. NEJM, 354(16): 1706-1723
Bhatt, D.L., Hulot, J., Moliterno, D.J., Harrington, R.A. (2014) Antiplatelet and Anticoagulation Therapy for Acute Coronary Syndromes. Circulation Research, 114(12): 1929-1943
Bonaca, M.P., Bhatt, D.L., Cohen, M. (2015) Long-Term Use of Ticagrelor in Patients with Prior Myocardial Infarction. New England Journal of Medicine, 372:1791-1800
Bonaca, M.P., Bhatt, D.L., Steg, P.G. (2016) Ischaemic risk and efficacy of ticagrelor in relation to time from P2Y12 inhibitor withdrawal in patients with prior myocardial infarction: insights from PEG-ASUS-TIMI 54. Eur Heart J, 37: 1133-1175
Brandt, J.T., Close, S.L., Iturria, S.J., Payne, C.D., Farid, N.A., Ernest, C.S., Lachno, D.R., Salazar, D., Winters, K.J. (2007) Common polymorphisms of CYP2C19 and CYP2C9 affect the pharmacokinetic and pharmacodynamic response to clopidogrel but not prasugrel. Journal of Thrombosis and Haemostasis, 5(12): 2429-2436
Cannon, C.P., Harrington, R.A., James, S. (2010) Comparison of ticagrelor with clopidogrel in patients with a planned invasive strategy for acute coronary syndromes (PLATO): a randomised doubleblind study. Lancet, 375: 283-93
CAPRIE Steering Committee (1996) A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet, 348(9038): 1329-1339
Cayla, G., Hulot, J.S., o'Connor Stephen, A., Pathak, A., Scott, S.A., Gruel, Y., Silvain, J., Vignalou, J., Huerre, Y., de la Briolle, A., Allanic, F., Beygui, F., Barthélémy, O., Montalescot, G. (2011) Clinical, Angiographic, and Genetic Factors Associated With Early Coronary Stent Thrombosis. JAMA, 306(16): 1765-74
Costa, F., Tijssen, J.G., Ariotti, S., Giatti, S. (2015) Derivation and validation of the predicting bleeding complications in patients undergoing stent implantation and subsequent dual antiplatelet therapy (PRECISE-DAPT) score: a pooled analysis of individual-patient datasets from clinical trials. J Am Heart Assoc, 4:e002524
Costa, F., van Klaveren, D., James, S., i dr. (2017) Derivation and validation of the predicting bleeding complications in patients undergoing stent implantation and subsequent dual antiplatelet therapy (PRECISE- DAPT) score: a pooled analysis of individual-patient datasets from clinical trials. Lancet, 389:1025-34
Ellis, S.G., Kereiakes, D.J., Metzger, D., Caputo, R.P., Rizik, D.G., Teirstein, P.S., Litt, M.R., Kini, A., Kabour, A., Marx, S.O., Popma, J.J., McGreevy, R., Zhang, Z., Simonton, C., Stone, G.W. (2015) Everolimus-Eluting Bioresorbable Scaffolds for Coronary Artery Disease. New England Journal of Medicine, 373(20): 1905-1915
Feres, F., Costa, R.A., Abizaid, A. (2013) Three vs Twelve Months of Dual Antiplatelet Therapy After Zotarolimus-Eluting Stents. JAMA, 310: 2510-2522
Fox, K.A., Mehta, S.R., Peters, R. (2004) Benefits and risks of the combination of clopidogrel and aspirin in patients undergoing surgical revascularization for non-ST-elevation acute coronary syndrome: the Clopidogrel in Unstable angina to prevent Recurrent ischemic Events (CURE) Trial. Circulation, 110: 1202-1208
Fuster, V., Badimon, L., Badimon, J.J. (1992) Mechanisms of disease -the pathogenesis of coronary-artery disease and the acute coronary syndromes. N Engl J, 326: 310-318
Gachet, C. (2001) ADP Receptors of Platelets and their Inhibition. Thrombosis and Haemostasis, 86(07): 222-232
Giustino, G., Baber, U., Sartori, S. (2015) Duration of dual antiplatelet therapy after drug-eluting stent implantation: a systematic review and meta-analysis of randomized controlled trials. J Am Coll Cardiol, 65: 1298-1310
Gurbel, P.A., Bliden, K.P., Hiatt, B.L. (2003) Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity. Circulation, 107: 2908-13
Gwon, H.C., Hahn, J.Y., Park, K.W. (2012) Six-month versus 12-month dual antiplatelet therapy after implantation of drug-eluting stents: the Efficacy of Xience/Promus Versus Cypher to Reduce Late Loss After Stenting (EXCELLENT) randomized, multicenter study. Circulation, 125: 505-513
Hansson, E.C., Jidéus, L., Åberg, B., Bjursten, H., Dreifaldt, M., Holmgren, A., Ivert, T., Nozohoor, S., Barbu, M., Svedjeholm, R., Jeppsson, A. (2016) Coronary artery bypass grafting-related bleeding complications in patients treated with ticagrelor or clopidogrel: a nationwide study. European Heart Journal, 37(2): 189-197
Held, C., Asenblad, N., Bassand, J.P. (2011) Ticagrelor versus clopidogrel in patients with acute coronary syndromes undergoing coronary artery bypass surgery: results from the PLATO (Platelet Inhibition and Patient Outcomes) trial. J Am Coll Cardiol, 57: 672-684
Hermiller, J.B., Krucoff, M.W., Kereiakes, D.J., Windecker, S., Steg, P., Yeh, R.W., Cohen, D.J., Cutlip, D.E., Massaro, J.M., Hsieh, W., Mauri, L. (2016) Benefits and Risks of Extended Dual Antiplatelet Therapy After Everolimus-Eluting Stents. JACC: Cardiovascular Interventions, 9(2): 138-147
James, S.K., Roe, M.T., Cannon, C.P., Cornel, J.H., Horrow, J., Husted, S., Katus, H., Morais, J., Steg, P.G., Storey, R.F., Stevens, S., Wallentin, L., Harrington, R.A. (2011) Ticagrelor versus clopidogrel in patients with acute coronary syndromes intended for non-invasive management: substudy from prospective randomised PLATelet inhibition and patient Outcomes (PLATO) trial. BMJ, 342(jun17 1): d3527-d3527
Jeong, Y.H., Kim, I.S., Park, Y. (2010) Carriage of cytochrome 2C19 polymorphism is associated with risk of high post-treatment platelet reactivity on high maintenance-dose clopidogrel of 150 mg/day: results of the ACCEL-DOUBLE (Accelerated Platelet Inhibition by a Double Dose of Clopidogr. J Am Coll Cardiol Intv, 3:731-41
Khan, N., Cox, A.R., Cotton, J.M. (2016) Pharmacokinetics and pharmacodynamics of oral P2Y12 inhibitors during the acute phase of a myocardial infarction: A systematic review. Thrombosis Research, 143: 141-148
Kim, B.K., Hong, M.K., Shin, D.H. (2012) A new strategy for discontinuation of dual antiplatelet therapy: the RESET Trial (REal Safety and Efficacy of 3-month dual antiplatelet Therapy following Endeavor zotarolimus-eluting stent implantation). J Am Coll Cardiol, 60: 1340-1348
Matetzky, S., Shenkman, B., Guetta, V., i dr. (2004) Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction. Circulation, 109:3171-5
Navarese, E.P., Andreotti, F., Schulze, V., Ko, O.M., Buffon, A., Brouwer, M., Costa, F., Kowalewski, M., Parati, G., Lip, G.Y. H., Kelm, M., Valgimigli, M. (2015) Optimal duration of dual antiplatelet therapy after percutaneous coronary intervention with drug eluting stents: meta-analysis of randomised controlled trials. BMJ, 350(apr16 25): h1618-h1618
Palmerini, T., Benedetto, U., Bacchi-Reggiani, L., Riva, D.D., Biondi-Zoccai, G., Feres, F., Abizaid, A., Hong, M., Kim, B., Jang, Y., Kim, H., Park, K.W., Genereux, P., Bhatt, D.L. (2015) Mortality in patients treated with extended duration dual antiplatelet therapy after drug-eluting stent implantation: a pairwise and Bayesian network meta-analysis of randomised trials. Lancet, 385(9985): 2371-2382
Räber, L., Brugaletta, S., Yamaji, K. (2015) Very late scaffold thrombosis: intracoronary imaging and histopathological and spectroscopic findings. J Am Coll Cardiol, 66: 1901-1915
Roe, M.T., Armstrong, P.W., Fox, K.A. (2012) Prasugrel versus clopidogrel for acute coronary syndromes without revascularization. N Engl J Med, 367: 1297-1309
Serebruany, V.L., Steinhubl, S.R., Berger, P.B. (2005) Variability in Platelet Responsiveness to Clopidogrel Among 544 Individuals. J Am Coll Cardiol, 45(2):246-51
Serruys, P.W., Chevalier, B., Sotomi, Y., Cequier, A., Carrié, D., Piek, J.J., van Boven, A.J., Dominici, M., Dudek, D., McClean, D., Helqvist, S., Haude, M., Reith, S., de Sousa, A.M., Campo, G. (2016) Comparison of an everolimus-eluting bioresorbable scaffold with an everolimus-eluting metallic stent for the treatment of coronary artery stenosis (ABSORB II): a 3 year, randomised, controlled, single-blind, multicentre clinical trial. Lancet, 388(10059): 2479-2491
Siller-Matula, J.M., Jilma, B., Schrör, K., Christ, G., Huber, K. (2010) Effect of proton pump inhibitors on clinical outcome in patients treated with clopidogrel: a systematic review and meta-analysis. Journal of Thrombosis and Haemostasis, 8(12): 2624-2641
Siller-Matula, J.M., Lang, I., Christ, G.I., Jilma, B. (2008) Calcium channel blockers reduce the antiplatelet effect of clopidogrel. BMC Pharmacology, 8(S1): 1557-63
Siller-Matula, J.M., Krumphuber, J., Jilma, B. (2010) Pharmacokinetic, pharmacodynamic and clinical profile of novel antiplatelet drugs targeting vascular diseases. British Journal of Pharmacology, 159(3): 502-517
Smith, P.K., Goodnough, L.T., Levy, J.H., Poston, R.S., Short, M.A., Weerakkody, G.J., Lenarz, L.A. (2012) Mortality Benefit With Prasugrel in the TRITON-TIMI 38 Coronary Artery Bypass Grafting Cohort. Journal of the American College of Cardiology, 60(5): 388-396
Steg, P.G., James, S., Harrington, R.A., Ardissino, D., Becker, R.C., Cannon, C.P., Emanuelsson, H., Finkelstein, A., Husted, S., Katus, H., Kilhamn, J., Olofsson, S., Storey, R.F., Weaver, W. (2010) Ticagrelor Versus Clopidogrel in Patients With ST-Elevation Acute Coronary Syndromes Intended for Reperfusion With Primary Percutaneous Coronary Intervention. Circulation, 122(21): 2131-2141
Task Force Members, Montalescot, G., Sechtem, U. (2013) ESC guidelines on the management of stable coronary artery disease: the Task Force on the management of stable coronary artery disease of the European Society of Cardiology. Eur Heart J, 34(38): 2949-3003
Tomsic, A., Schotborgh, M.A., Manshanden, J.S. (2016) Coronary artery bypass grafting-related bleeding complications in patients treated with dual antiplatelet treatment. Eur J Cardiothorac Surg, 50: 849-56
Udell, J.A., Bonaca, M.P., Collet, J.P., Lincoff, A., Kereiakes, D.J., Costa, F., Lee, C.W., Mauri, L., Valgimigli, M., Park, S., Montalescot, G., Sabatine, M.S., Braunwald, E., Bhatt, D.L. (2016) Long-term dual antiplatelet therapy for secondary prevention of cardiovascular events in the subgroup of patients with previous myocardial infarction: a collaborative meta-analysis of randomized trials. European Heart Journal, 37:390-9
Valgimigli, M., Bueno, H., Byrne, R.A. (2017) ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS: The Task Force for dual antiplatelet therapy in coronary artery disease of the European Society of Cardiology (ESC) and of the European. Eur Heart J
Valgimigli, M., Campo, G., Monti, M., Vranckx, P., Percoco, G., Tumscitz, C., Castriota, F., Colombo, F., Tebaldi, M., Fucà, G., Kubbajeh, M., Cangiano, E., Minarelli, M., Scalone, A., Cavazza, C. (2012) Short- Versus Long-Term Duration of Dual-Antiplatelet Therapy After Coronary Stenting. Circulation, 125(16): 2015-2026
Vane, J.R., Botting, R.M. (2003) The mechanism of action of aspirin. Thrombosis Research, 110(5-6): 255-258
Wallentin, L., Becker, R.C., Budaj, A. (2009) Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med, 361: 1045-57
Wiviott, S.D., Braunwald, E., McCabe, C.H., Montalescot, G., Ruzyllo, W., Gottlieb, S., Neumann, F., Ardissino, D., de Servi, S., Murphy, S.A., Riesmeyer, J., Weerakkody, G., Gibson, C. (2007) Prasugrel versus Clopidogrel in Patients with Acute Coronary Syndromes. New England Journal of Medicine, 357(20): 2001-2015
Yusuf, S., Zhao, F., Mehta, S.R. (2001) Effects of Clopidogrel in Addition to Aspirin in Patients with Acute Coronary Syndromes without ST-Segment Elevation. New England Journal of Medicine, 345(7): 494-502
 

About

article language: English
document type: Review Paper
DOI: 10.5937/siks1802045R
published in SCIndeks: 12/05/2019

Related records

Medicinska istraživanja (2015)
Pharmacogenetics in clinical practice: Challenges and opportunities
Dragović Gordana, et al.

Racion ter (2013)
Importance of pharmacogenetics for therapeutic use of clopidogrel
Rančić Nemanja, et al.

Srce i krvni sudovi (2011)
Antithrombotic therapy in secondary prevention
Aleksandrić Srđan, et al.

show all [4]